Login to Your Account



Vaccinex Financing Targets $25M, Signs Deal With Teva

By Randall Osborne


Wednesday, February 28, 2007
The potential multiple-sclerosis application of Vaccinex Inc.'s preclinical antibody VX15 drew interest from Teva Pharmaceuticals Inc., which is taking part in an anticipated $25 million-plus financing round while entering a deal with Vaccinex to develop and sell the drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription